University Health Network, Toronto
The purpose of this study is to collect data on how advanced and rare cancers respond to biomarker-based treatments.
Advanced Cancer
Rare Diseases
Patient-specific treatments
The UNIQUE umbrella protocol is an overarching framework to study precision medicine in patients with precise molecular data, who have exhausted all established treatment options and who are not eligible for any of the ongoing trials. There is no additional visit or procedure required to participate in this study. Participants who have received/who may receive the following treatments may join the study and will be assigned to a study cohort (group): * Group 1 - Health Canada approved/marketed drug(s) used on or off-label as Standard of Care (SOC) * Group 2 - Drugs accessed from Special Access Program (SAP) * Group 3 - Non-marketed investigational agents Under the UNIQUE framework, data from participants will be evaluated. The following data will be collected: * Demographic data (for example: sex, race, month and year of birth) * Medical history * Cancer characteristics including biomarkers * Treatment history * response to treatment
| Study Type : | OBSERVATIONAL |
| Estimated Enrollment : | 400 participants |
| Official Title : | UNIQUE: Umbrella N-of-1 Tumor Trials - Umbrella Protocol for Oncology Single Patient Protocols |
| Actual Study Start Date : | 2024-02-01 |
| Estimated Primary Completion Date : | 2027-02-01 |
| Estimated Study Completion Date : | 2029-02-01 |
Information not available for Arms and Intervention/treatment
| Ages Eligible for Study: | 18 Years |
| Sexes Eligible for Study: | ALL |
| Accepts Healthy Volunteers: |
Want to participate in this study, select a site at your convenience, send yourself email to get contact details and prescreening steps.
RECRUITING
University Health Network, Princess Margaret Cancer Centre
Toronto, Ontario, Canada, M5G 2M9